Prescription Drug Benefit and Cost Containment Act of 2003
Latest action · Jan 7, 2003 Read twice and referred to the Committee on Finance.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJan 7, 2003
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Provides for: (1) part D benefits under Medicare+Choice plans under Medicare part C (Medicare+Choice); and (2) Medicare cost-sharing and other assistance for low-income individuals.
Revises requirements for Medicare supplemental insurance policy (Medigap) benefit packages to conform to changes made by this Act.
Provides for coverage of immunosuppressive drugs for all Medicare beneficiaries under Medicare part B (Supplementary Medical Insurance).
Directs the Secretary of Health and Human Services to study and report to Congress on the feasibility and advisability of establishing a uniform format for pharmacy benefit cards provided to beneficiaries.
Expands the membership and duties of the Medicare Payment Advisory Commission (MEDPAC).
Amends the Federal Food, Drug, and Cosmetic Act to revise provisions concerning the timing of generic drug availability.
Requires applicants (pharmaceutical companies) to register their patents with the Food and Drug Administration (FDA) within 30 days of approval (or issuance for subsequently issued patents). Makes failure to timely register a bar to civil actions for patent infringement.
Requires applications for new drugs (NDA) or abbreviated new drug applications (ANDA) which rely upon investigations not conducted by or for the applicant and which concern a patent that claims both the drug and a method of use or more than one method of use to include a certification on a claim-by-claim basis that the patent is invalid or will not be infringed (known as a Paragraph IV filing/certification) by the new drug's (generic) manufacture and a statement regarding the method(s) of use claim.
Prohibits (for subsequently issued patents) an extension of the 30-month stay of FDA approval for any new drug where an ANDA or NDA contains a Paragraph IV filing/certification and the patent holder indicates an intention to bring a patent infringement suit against the new (generic) drug's manufacturer. Makes failure to timely file a civil action for infringement a bar to later action.
Requires the first generic applicant with a Paragraph IV filing to forfeit the 180 day marketing exclusivity period to a subsequent generic applicant if the first generic applicant engages in certain behaviors (forfeiture events) which delay or prevent the marketing of the generic drug.
Adds provisions on importation of prescription drugs and pediatric labeling of drugs and biological products.
Cosponsors 21
Members who signed on, in the order they did. Signatures ran from Jan 7, 2003 to Apr 2, 2003; 17 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-MD | Barbara A. Mikulski | Original | Jan 7, 2003 |
| D-MI | Carl Levin | Original | Jan 7, 2003 |
| D-NY | Charles E. Schumer | Original | Jan 7, 2003 |
| D-HI | Daniel K. Akaka | Original | Jan 7, 2003 |
| D-MI | Debbie Stabenow | Original | Jan 7, 2003 |
| D-MA | Edward M. Kennedy | Original | Jan 7, 2003 |
| D-NJ | Frank R. Lautenberg | Original | Jan 7, 2003 |
| D-NV | Harry Reid | Original | Jan 7, 2003 |
| D-NY | Hillary Rodham Clinton | Original | Jan 7, 2003 |
| D-RI | Jack Reed | Original | Jan 7, 2003 |
| D-WV | John D. Rockefeller IV | Original | Jan 7, 2003 |
| D-NJ | Jon S. Corzine | Original | Jan 7, 2003 |
| D-MN | Mark Dayton | Original | Jan 7, 2003 |
| D-VT | Patrick J. Leahy | Original | Jan 7, 2003 |
| D-MD | Paul S. Sarbanes | Original | Jan 7, 2003 |
| D-IL | Richard J. Durbin | Original | Jan 7, 2003 |
| D-SD | Tim Johnson | Original | Jan 7, 2003 |
| D-CA | Barbara Boxer | Jan 9, 2003 | |
| D-CT | Christopher J. Dodd | Jan 9, 2003 | |
| D-WV | Robert C. Byrd | Feb 26, 2003 | |
| D-FL | Bill Nelson | Apr 2, 2003 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Finance Committee | Referred Jan 7, 2003 |
Actions 3
Everything that happened, newest first.
- Jan 7, 2003Introduced in Senate
- Jan 7, 2003Sponsor introductory remarks on measure. (CR 1/9/2003 S134)
- Jan 7, 2003Read twice and referred to the Committee on Finance.
In the Congressional Record 1
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| Senate | Debate and remarks S134–S136 | Thomas A. Daschle D-SD | Jan 9, 2003 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Printed hearings 2
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| S. Hrg. 108-809 | ADDRESSING THE NEW REALITY OF CURRENT VISA POLICY ON INTERNATIONAL STUDENTS AND RESEARCHERS104 pages | Foreign Relations Committee | Oct 6, 2004 |
| S. Hrg. 108-370 | ANTI-SEMITISM IN EUROPE144 pages | Foreign Relations Committee | Oct 22, 2003 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to amend title XVIII of the Social Security Act to provide coverage of outpatient prescription drugs under the medicare program and to amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals, and for other purposes.
- Short Titles as Introduced
- Prescription Drug Benefit and Cost Containment Act of 2003
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative procedure
- Ambulatory care
- Armed Forces and National Security
- Auditing
- Business records
- Canada
- Child health
- Civil Rights and Liberties, Minority Issues
- Commerce
- Communication in medicine
- Conflict of interests
- Congress
- Congressional reporting requirements
- Consent decrees
- Consumer education
- Consumer organizations
- Continuum of care
- Crime and Law Enforcement
- Department of Health and Human Services
- District of Columbia
- Drug advertising
- Drug approvals
- Drug industry
- Drug interactions
- Drug therapy
- Drugs
- Economics and Public Finance
- Education
- Electronic data interchange
- Emergency medicine
- Employee benefit plans
- Employee health benefits
- Families
- Federal advisory bodies
- Federal aid to health facilities
- Federal Trade Commission
- Fees
- Finance and Financial Sector
- Fines (Penalties)
- Fraud
- Generic drugs
- Government Operations and Politics
- Government trust funds
- Governmental investigations
- Grants-in-aid
- Health
- Health care fraud
- Health education
- Health information systems
- Health insurance
- Health insurance continuation
- Health maintenance organizations
- Health services administration
- Home care services
- Hospitals
- Housing and Community Development
- Immunosuppressive drugs
- Imports
- Independent regulatory commissions
- Information networks
- Injunctions
- Intellectual property
- Judicial opinions
- Judicial review
- Kidney diseases
- Labeling
- Labor and Employment
- Law
- Mail-order business
- Managed care
- Marketing
- Medicaid
- Medical economics
- Medical fees
- Medical records
- Medical statistics
- Medicare
- Medication abuse
- Medigap
- Metropolitan areas
- Patent infringement
- Patents
- Patients' rights
- Pharmaceutical research
- Pharmacies
- Prescription pricing
- Quality control
- Rebates
- Restrictive trade practices
- Retiree health benefits
- Right of petition
- Right of privacy
- Rural health
- Science, Technology, Communications
- Social Welfare
- Standards
- Surveys
- Technological innovations
- Territories (U.S.)
- Transplantation of organs, tissues, etc.
- Urban affairs
- Veterans' benefits
- Veterans' medical care
Text 1
Each version as it was printed, newest first.
- Jan 7, 2003Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.